[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.167.137. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
December 18, 1991

More on Desert Storm-Reply

Author Affiliations

US Army Medical Research Institute of Chemical Defense Aberdeen Proving Ground, Md

US Army Medical Research Institute of Chemical Defense Aberdeen Proving Ground, Md

JAMA. 1991;266(23):3283. doi:10.1001/jama.1991.03470230040016
Abstract

In Reply.  —We limit our response to Dr Sarno to issues raised about pyridostigmine. Clearly, this is of concern as the number of women in military service increases and the threat of chemical warfare in the world persists. Since the safety of pyridostigmine during pregnancy or lactation in humans has not been established, the use of pyridostigmine in women who may become pregnant requires weighing the drug's potential benefits (ie, survival in a nerve agent attack) against its possible hazards to mother and child.Sarno stated that pyridostigmine is classified as risk factor C because no controlled studies in women have been done, or because studies in women and animals are not available.1 In fact, controlled studies in rats and monkeys have been done and showed no direct teratogenic effects or significant ill effects on fertility and reproductive performance (Hoffman-La Roche Inc, proprietary information).2Importantly, pyridostigmine has been

×